These approaches increased short-term survival and progression-free survival related to a functional tumor-specific T-cell response, with a predominant T cytotoxic(Nestle et al., 1998; Tel et al., 2013; Schreibelt et al., 2015) and helper profiles (IFNγ, Th1, and IL-17, Th17 cells) (Escobar et al., 2005; Durán-Aniotz et al., 2013; Lo et al., 2019) and a marked reduction in the proportion of CD4 transforming growth factor (TGF) β+ regulatory T cells(Lo et al., 2019). Here, CD4 is linked to neoplasm.